drugset / Trial / NCT02361138
The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in healthy subjects.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozin | Small molecule | 1.25 mg | — |
| Subject | Henagliflozin | Small molecule | 2.5 mg | — |
| Subject | Henagliflozin | Small molecule | 5 mg | — |
| Subject | Henagliflozin | Small molecule | 10 mg | — |
| Subject | Henagliflozin | Small molecule | 25 mg | — |
| Subject | Henagliflozin | Small molecule | 100 mg | — |